pSivida Corp. (NASDAQ:PSDV) – Equities researchers at B. Riley raised their Q3 2018 earnings per share (EPS) estimates for pSivida in a report released on Thursday. B. Riley analyst A. D’silva now forecasts that the company will post earnings of ($0.14) per share for the quarter, up from their prior forecast of ($0.15). B. Riley currently has a “Buy” rating and a $5.00 target price on the stock. B. Riley also issued estimates for pSivida’s Q4 2018 earnings at ($0.12) EPS and FY2018 earnings at ($0.54) EPS.
Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of pSivida in a research note on Wednesday, November 8th. Laidlaw started coverage on shares of pSivida in a report on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price on the stock. Northland Securities reiterated a “buy” rating and set a $10.00 target price on shares of pSivida in a report on Monday, December 11th. Finally, ValuEngine cut shares of pSivida from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $7.57.
pSivida (NASDAQ:PSDV) remained flat at $$1.04 during trading on Monday. 118,200 shares of the company’s stock were exchanged, compared to its average volume of 407,118. The company has a market cap of $46.17, a PE ratio of -1.73 and a beta of 1.26. pSivida has a twelve month low of $0.93 and a twelve month high of $2.45.
pSivida (NASDAQ:PSDV) last issued its earnings results on Wednesday, February 7th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.48 million. pSivida had a negative net margin of 882.37% and a negative return on equity of 205.82%.
An institutional investor recently bought a new position in pSivida stock. OxFORD Asset Management LLP acquired a new stake in pSivida Corp. (NASDAQ:PSDV) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida at the end of the most recent quarter. Hedge funds and other institutional investors own 10.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Q3 2018 Earnings Forecast for pSivida Corp. Issued By B. Riley (PSDV)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/q3-2018-earnings-forecast-for-psivida-corp-issued-by-b-riley-psdv.html.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.